Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease

被引:13
|
作者
Ladhani, Shamez [1 ]
Neely, Fiona [2 ]
Heath, Paul T. [3 ,4 ]
Nazareth, Bernadette [5 ]
Roberts, Richard [6 ]
Slack, Mary P. E. [7 ]
McVernon, Jodie [8 ]
Ramsay, Mary E. [1 ]
机构
[1] Hlth Protect Agcy, Ctr Infect, Immunisat Dept, London NW9 5EQ, England
[2] Hampshire & Isle Wight Hlth Protect Unit, Whiteley PO15 7AB, England
[3] Univ London, Vaccine Inst, London SW17 0RE, England
[4] Univ London, Div Child Hlth, London SW17 0RE, England
[5] Norfolk Suffolk & Cambridgeshire Hlth Protect Uni, Huntingdon PE29 6FH, England
[6] Natl Publ Hlth Serv Wales, Cardiff CF10 3NW, S Glam, Wales
[7] Hlth Protect Agcy, Ctr Infect, Haemophilus Reference Unit, London NW9 5EQ, England
[8] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne Sch Populat Hlth, Vaccine & Immunisat Res Grp, Melbourne, Vic 3010, Australia
关键词
Haemophilus influenzae; Hib; Prevention; Contacts; Rifampicin; DAY-CARE-CENTER; HEMOPHILUS-INFLUENZAE; RIFAMPIN PROPHYLAXIS; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE; HOUSEHOLD CONTACTS; PHARYNGEAL COLONIZATION; STREPTOCOCCUS-PNEUMONIAE; OROPHARYNGEAL CARRIAGE; ANTIBIOTIC-RESISTANCE;
D O I
10.1016/j.jinf.2008.10.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Haemophilus influenzae serotype b (Hib) can cause severe life threatening disease in healthy individuals, with over 80% of cases in the pre-vaccine era occurring in children under five years of age. The introduction of Hib conjugate vaccine into routine childhood immunisation programmes has resulted in a dramatic reduction in the incidence of invasive Hib disease across all age groups. The objective of this paper is to update existing UK guidelines on the prevention of Hib disease among contacts of an index case by reviewing the original literature and the current epidemiology of Hib carriage and invasive disease. Household contacts of individuals who develop invasive Hib disease are at higher risk of developing secondary Hib infection themselves, particularly if the contact is a young child or is immunosuppressed. Pre-school contacts of young children with invasive Hib disease are also at higher risk of developing secondary Hib infection. Rifampicin at a dose of 20 mg/kg/day for 4 days is highly effective in eradicating pharyngeal carriage of Hib and reducing the risk of invasive Hib disease among household and pre-school contacts. Children under 10 years of age who develop invasive Hib disease should also receive rifampicin chemoprophylaxis to eliminate carriage and have Hib antibody levels tested around four weeks after infection. Hib vaccine failure cases should additionally have immunoglobulin concentrations measured and be assessed for evidence of an immune deficiency. If there is a vulnerable individual (child younger than 10 years or an immunosuppressed or asplenic individual of any age) among the household contacts of a case, all members of that household, including the index case, should receive chemoprophylaxis. All children younger than 10 years in the household should be appropriately vaccinated against Hib. Where more than one case occurs in a pre-school or primary school setting, chemoprophytaxis should be offered to all room contacts (including staff), and un-immunised and partially immunised children younger than 10 years should complete their primary immunisations, including a booster dose, as soon as possible. Families of children attending the same pre-school or primary school as an index case should be advised to seek medical advice if their child becomes unwell. (C) 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 50 条
  • [1] Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease
    Gkentzi, Despoina
    Collins, Sarah
    Ramsay, Mary E.
    Slack, Mary P. E.
    Ladhani, Shamez
    [J]. JOURNAL OF INFECTION, 2013, 67 (05) : 486 - 489
  • [2] Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease
    Gilsdorf, Janet R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 224 : S321 - S330
  • [3] Haemophilus influenzae type B (HiB) is back
    Hanousek, J
    Swart, M
    [J]. ANAESTHESIA, 2003, 58 (08) : 813 - 814
  • [4] NTAGI Subcommittee Recommendations on Haemophilus influenzae Type b (Hib) Vaccine Introduction in India
    Muliyil, J. P.
    Bhan, M. K.
    Bhattacharya, S. K.
    Kant, Lalit
    Arora, N. K.
    Santosham, M.
    Cherian, Thomas
    Dutta, Ashok
    John, Jacob
    Jafari, Hamid
    Thacker, Naveen
    Padmanaban
    Senthilmazhan, M.
    Suresh, Saradha
    Kapoor, Ambujam Nair
    Upadhaya, Sanjeev
    Rao, Krishna
    Abbas, Syed
    Agarwal, R. K.
    Gambhir, Ajay
    Spanner, Soren
    Gupta, Satish
    Bahl, Sunil
    Gera, Rajeev
    Numgyal, Pem
    Francis, Paul
    Lahariya, Chandrakant
    Sharma, Shamila
    Kumar, Harish
    Peterson, Tim
    [J]. INDIAN PEDIATRICS, 2009, 46 (11) : 945 - 954
  • [5] Risk of Invasive Haemophilus influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine Era
    Nix, Eli B.
    Hawdon, Nicole
    Gravelle, Sean
    Biman, Birubi
    Brigden, Malcolm
    Malik, Saleem
    McCready, William
    Ferroni, Garry
    Ulanova, Marina
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (05) : 766 - 771
  • [6] Estimating the Haemophilus influenzae type b (Hib) disease burden and the impact of Hib vaccine in Fiji
    Wilson, N
    Mansoor, O
    Wenger, J
    Martin, R
    Zanardi, L
    O'Leary, M
    Rabukawaqa, V
    [J]. VACCINE, 2003, 21 (17-18) : 1907 - 1912
  • [7] DECLINE OF CHILDHOOD HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN THE HIB VACCINE ERA
    ADAMS, WG
    DEAVER, KA
    COCHI, SL
    PLIKAYTIS, BD
    ZELL, ER
    BROOME, CV
    WENGER, JD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02): : 221 - 226
  • [8] EPIDEMIOLOGY OF INVASIVE HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN ISRAEL
    DAGAN, R
    [J]. VACCINE, 1993, 11 : S43 - S45
  • [9] Immune response of adults with secondary immunodeficiency to pediatric Haemophilus influenzae type b (Hib) vaccine
    Marina Ulanova
    Nicole Hawdon
    Eli Nix
    Garry Ferroni
    William McCready
    [J]. Allergy, Asthma & Clinical Immunology, 7 (Suppl 2)